Limits...
Aberrant over-expression of TRPM7 ion channels in pancreatic cancer: required for cancer cell invasion and implicated in tumor growth and metastasis.

Yee NS, Kazi AA, Li Q, Yang Z, Berg A, Yee RK - Biol Open (2015)

Bottom Line: Anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma significantly correlates with the size and stages of tumors.In human pancreatic adenocarcinoma cells in which TRPM7 is highly expressed, short hairpin RNA-mediated suppression of TRPM7 impairs cell invasion.The results demonstrate that TRPM7 channels are over-expressed in a proportion of the pre-malignant lesions and malignant tumors of the pancreas, and they are necessary for invasion by pancreatic cancer cells.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology-Oncology, Department of Medicine, Penn State College of Medicine, Program of Experimental Therapeutics, Penn State Hershey Cancer Institute, Penn State Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA 17033, USA nyee@hmc.psu.edu.

No MeSH data available.


Related in: MedlinePlus

Anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma positively correlates with tumor size and stages.The distribution of the IHC score for expression of TRPM7 is displayed against (A) age or gender, (B) histological grade, (C) primary tumor [size], and (D) stage. The total number of specimens of pancreatic adenocarcinoma examined is 282. (C) Polyserial correlation between the primary tumor size (T) and the log-transformed IHC score is 0.24. (D) Polyserial correlation between the tumor stages and the log-transformed IHC score is 0.26. *P-values indicate statistically significant positive association of primary tumor size (T) or tumor stages with the anti-TRPM7 IHC score. The bars represent mean and s.e.m.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4400593&req=5

f04: Anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma positively correlates with tumor size and stages.The distribution of the IHC score for expression of TRPM7 is displayed against (A) age or gender, (B) histological grade, (C) primary tumor [size], and (D) stage. The total number of specimens of pancreatic adenocarcinoma examined is 282. (C) Polyserial correlation between the primary tumor size (T) and the log-transformed IHC score is 0.24. (D) Polyserial correlation between the tumor stages and the log-transformed IHC score is 0.26. *P-values indicate statistically significant positive association of primary tumor size (T) or tumor stages with the anti-TRPM7 IHC score. The bars represent mean and s.e.m.

Mentions: To determine the clinical significance of TRPM7 in pancreatic adenocarcinoma, we further analyzed the expression of TRPM7 in detail and correlated it with the clinical and pathological features. The characteristics of the 282 cases of pancreatic adenocarcinoma present in the tissue microarrays are listed in Table 2. On the basis of the percent coverage by IHC separated by staining intensity and tumor stages, the expression levels of TRPM7 in pancreatic adenocarcinoma are displayed (Table 3). The majority of the pancreatic adenocarcinoma specimens (66%) exhibit moderate to high anti-TRPM7 immunoreactivity (Fig. 3). A positive correlation between the expression levels of TRPM7 and the primary tumor size and tumor stages was identified (Fig. 4). In particular, there is significantly higher anti-TRPM7 immunoreactivity in the primary tumor at T3 than at T2 (P = 0.00044). Similarly, the expression levels of TRPM7 in stage II tumors or stage IV tumors are significantly higher than in stage I (P = 0.00017 and P = 0.03, respectively). There is no significant correlation between the expression levels of TRPM7 and the age and gender of the patients or histological grade (Fig. 4).


Aberrant over-expression of TRPM7 ion channels in pancreatic cancer: required for cancer cell invasion and implicated in tumor growth and metastasis.

Yee NS, Kazi AA, Li Q, Yang Z, Berg A, Yee RK - Biol Open (2015)

Anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma positively correlates with tumor size and stages.The distribution of the IHC score for expression of TRPM7 is displayed against (A) age or gender, (B) histological grade, (C) primary tumor [size], and (D) stage. The total number of specimens of pancreatic adenocarcinoma examined is 282. (C) Polyserial correlation between the primary tumor size (T) and the log-transformed IHC score is 0.24. (D) Polyserial correlation between the tumor stages and the log-transformed IHC score is 0.26. *P-values indicate statistically significant positive association of primary tumor size (T) or tumor stages with the anti-TRPM7 IHC score. The bars represent mean and s.e.m.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4400593&req=5

f04: Anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma positively correlates with tumor size and stages.The distribution of the IHC score for expression of TRPM7 is displayed against (A) age or gender, (B) histological grade, (C) primary tumor [size], and (D) stage. The total number of specimens of pancreatic adenocarcinoma examined is 282. (C) Polyserial correlation between the primary tumor size (T) and the log-transformed IHC score is 0.24. (D) Polyserial correlation between the tumor stages and the log-transformed IHC score is 0.26. *P-values indicate statistically significant positive association of primary tumor size (T) or tumor stages with the anti-TRPM7 IHC score. The bars represent mean and s.e.m.
Mentions: To determine the clinical significance of TRPM7 in pancreatic adenocarcinoma, we further analyzed the expression of TRPM7 in detail and correlated it with the clinical and pathological features. The characteristics of the 282 cases of pancreatic adenocarcinoma present in the tissue microarrays are listed in Table 2. On the basis of the percent coverage by IHC separated by staining intensity and tumor stages, the expression levels of TRPM7 in pancreatic adenocarcinoma are displayed (Table 3). The majority of the pancreatic adenocarcinoma specimens (66%) exhibit moderate to high anti-TRPM7 immunoreactivity (Fig. 3). A positive correlation between the expression levels of TRPM7 and the primary tumor size and tumor stages was identified (Fig. 4). In particular, there is significantly higher anti-TRPM7 immunoreactivity in the primary tumor at T3 than at T2 (P = 0.00044). Similarly, the expression levels of TRPM7 in stage II tumors or stage IV tumors are significantly higher than in stage I (P = 0.00017 and P = 0.03, respectively). There is no significant correlation between the expression levels of TRPM7 and the age and gender of the patients or histological grade (Fig. 4).

Bottom Line: Anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma significantly correlates with the size and stages of tumors.In human pancreatic adenocarcinoma cells in which TRPM7 is highly expressed, short hairpin RNA-mediated suppression of TRPM7 impairs cell invasion.The results demonstrate that TRPM7 channels are over-expressed in a proportion of the pre-malignant lesions and malignant tumors of the pancreas, and they are necessary for invasion by pancreatic cancer cells.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology-Oncology, Department of Medicine, Penn State College of Medicine, Program of Experimental Therapeutics, Penn State Hershey Cancer Institute, Penn State Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA 17033, USA nyee@hmc.psu.edu.

No MeSH data available.


Related in: MedlinePlus